Lilly in the NEWS
INDIANAPOLIS, December 1, 2025, Eli Lilly and Company (LLY) today announced Zepbound® (tirzepatide) single-dose vials will now be available at lower prices on LillyDirect, the company’s digital healthcare platform. This update builds on Lilly’s ongoing efforts to lower out-of-pocket costs for people living with obesity in the United States.
Last month, Lilly announced lower prices for Zepbound multi-dose pens, subject to approval by the FDA. By lowering prices of Zepbound single-dose vials, Lilly is offering patients greater access and optionality with their treatment options.
With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per month. The 5 mg dose will be available at $399 per month. All other approved doses are $449 per month for patients in the Zepbound Self Pay Journey Program.
From Eli Lilly
Ilya Yuffa, executive vice president and president, Lilly USA and Global Customer Capabilities, Said“ Far too many people who need obesity treatments still face cost and coverage barriers. Today’s action underscores Lilly’s commitment to improving access across the obesity care landscape. We will keep working to provide more options – expanding choices for delivery devices and creating new pathways for access – so more people can get the medicines they need.”
| Zepbound Self Pay Journey Program* via LillyDirect |
|
| |
Dose |
New Price |
Prior Price |
|
| |
2.5 mg |
$299 |
$349 |
|
| |
5 mg |
$399 |
$499 |
|
| |
7.5 mg |
$449 |
$499 |
|
| |
10 mg |
$449 |
$499 |
|
| |
12.5 mg |
$449 |
$499 |
|
| |
15 mg |
$449 |
$499 |
|
|
|
|
|
|
|
*Regular prices (per month) when not purchased via the Zepbound Self-Pay Journey Program: $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg, $1,049 for 15 mg.
About Zepbound
Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. It may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known whether Zepbound is safe and effective for use in children.
Zepbound Availability
Zepbound is also available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL doses in a single-doseautoinjector pen. The 2.5 mg is a starting dose and not an approved maintenance dose. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg injected subcutaneously once per week for weight reduction and long-term maintenance.
The recommended maintenance doses are 10 mg or 15 mg for OSA.
Additional resources and details are available on Zepbound.lilly.com
Visit LillyDirect.lilly.com to learn more about pricing, eligibility and delivery options.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. Lilly has been pioneering life-changing discoveries for nearly 150 years. Today, Lilly’s products help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.
With each step toward a healthier world, Lilly is motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/news, or follow the Company on Facebook, Instagram, and LinkedIn.
Trademarks and Trade Names
All trademarks or trade names referred to in this standby statement are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company’s or their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Please read Cautionary Statement Regarding Forward-Looking Statements at Lilly’s website.
Prohost Observations
During its 150 years, LLY has never gotten old. The longer this firm lives, the more it adds knowledge and increases its capability towards bringing products that can treat untreatable severe and life-threatening diseases.
Lilly Stock
| Stock Symbol |
LLY |
| Stock Price |
$1,056.82 |
| Market Cap. |
$1.01 trillion |
| 52-Week High |
$1,111.99 |
| 52-Week Low |
$623.78 |
| Prohost Target |
$1,035 |
Currently, it appears difficult, except for the rich, to buy Eli Lilly stock right now with its high price. However, it is not wrong to keep an eye on this company’s stock price. It could divide the stocks’ numbers. It could plummet, making it possible for moderate people to buy.
Click here to read more about Eli Lilly.
News & Comments
December 1, 2025
Eli Lilly Lowers the Price of Zepbound® (tirzepatide) Single-Dose Vials
Lilly in the NEWS
INDIANAPOLIS, December 1, 2025, Eli Lilly and Company (LLY) today announced Zepbound® (tirzepatide) single-dose vials will now be available at lower prices on LillyDirect, the company’s digital healthcare platform. This update builds on Lilly’s ongoing efforts to lower out-of-pocket costs for people living with obesity in the United States.
Last month, Lilly announced lower prices for Zepbound multi-dose pens, subject to approval by the FDA. By lowering prices of Zepbound single-dose vials, Lilly is offering patients greater access and optionality with their treatment options.
With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per month. The 5 mg dose will be available at $399 per month. All other approved doses are $449 per month for patients in the Zepbound Self Pay Journey Program.
From Eli Lilly
Ilya Yuffa, executive vice president and president, Lilly USA and Global Customer Capabilities, Said“ Far too many people who need obesity treatments still face cost and coverage barriers. Today’s action underscores Lilly’s commitment to improving access across the obesity care landscape. We will keep working to provide more options – expanding choices for delivery devices and creating new pathways for access – so more people can get the medicines they need.”
*Regular prices (per month) when not purchased via the Zepbound Self-Pay Journey Program: $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg, $1,049 for 15 mg.
About Zepbound
Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. It may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known whether Zepbound is safe and effective for use in children.
Zepbound Availability
Zepbound is also available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL doses in a single-doseautoinjector pen. The 2.5 mg is a starting dose and not an approved maintenance dose. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg injected subcutaneously once per week for weight reduction and long-term maintenance.
The recommended maintenance doses are 10 mg or 15 mg for OSA.
Additional resources and details are available on Zepbound.lilly.com
Visit LillyDirect.lilly.com to learn more about pricing, eligibility and delivery options.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. Lilly has been pioneering life-changing discoveries for nearly 150 years. Today, Lilly’s products help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.
With each step toward a healthier world, Lilly is motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/news, or follow the Company on Facebook, Instagram, and LinkedIn.
Trademarks and Trade Names
All trademarks or trade names referred to in this standby statement are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company’s or their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Please read Cautionary Statement Regarding Forward-Looking Statements at Lilly’s website.
Prohost Observations
During its 150 years, LLY has never gotten old. The longer this firm lives, the more it adds knowledge and increases its capability towards bringing products that can treat untreatable severe and life-threatening diseases.
Lilly Stock
Currently, it appears difficult, except for the rich, to buy Eli Lilly stock right now with its high price. However, it is not wrong to keep an eye on this company’s stock price. It could divide the stocks’ numbers. It could plummet, making it possible for moderate people to buy.
Click here to read more about Eli Lilly.
Other Articles